|
Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Carevive Systems |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; EMD Serono; Genentech; Incyte; Merck; Pfizer; Tesaro; Xcovery |
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Xcovery |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb; Genentech; MSD Oncology |
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; MSD Oncology |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis |
Research Funding - Bristol-Myers Squibb; Incyte |
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy |
Travel, Accommodations, Expenses - Genentech |